BioCentury | Oct 30, 2020
Finance

Oct. 29 Quick Takes: Ultragenyx, Scholar Rock, Galecto, Citrine-Bioprojet, miRagen-Viridian, Elpis, CASI-BioInvent

Ultragenyx, Scholar Rock offerings Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and Scholar Rock Holding Corp. (NASDAQ:SRRK) raised follow-ons late Wednesday. Ultragenyx raised $400 million, while Scholar Rock raised $200 million via the shares and prefunded warrants after its stock more...
BioCentury | May 12, 2020
Deals

bluebird hopes tough choices today will keep core programs on track

To ensure it can meet its goal of launching four programs by 2022 amid the coronavirus crisis, bluebird has retooled its BCMA CAR T deal with Bristol Myers, opting for $200 million of cash now...
BioCentury | Dec 14, 2019
Product Development

BCMA programs begin to find their niches

As CAR Ts, bispecifics and ADCs targeting BCMA battle it out in multiple myeloma, the question is not which modality will win, but whether they can fill different niches in the treatment landscape. The safety...
BioCentury | Dec 10, 2019
Clinical News

ASH sets up multiple anti-BCMA opportunities for MM patients

BCMA-targeted agents to treat multiple myeloma once again took center stage at ASH as more companies and modalities continue to pile into the space, setting up several options for patients and physicians based on trade-offs...
BioCentury | Aug 15, 2019
Company News

Harmony crosses finish line with Wakix for narcolepsy

FDA approved Wakix pitolisant Thursday, almost two years after Harmony gained U.S. rights to the narcolepsy drug. During 2017-18, Harmony raised $295 million to push it through registration. In October 2017, Harmony Biosciences LLC (Plymouth...
BioCentury | Dec 16, 2017
Product Development

Assessing the BCMA scene

Differences in patient populations and a dearth of clinical outcome data mean it’s too soon to declare bluebird bio Inc.’s anti-BCMA chimeric antigen receptor therapy the leader of the pack of CARs that presented clinical...
BioCentury | Oct 13, 2017
Financial News

Harmony raises $270M, licenses narcolepsy drug

On Oct. 6, CNS company Harmony Biosciences LLC (Plymouth Meeting, Pa.) said it raised $270 million in an equity round from Valor Equity Partners, Fidelity Management & Research Co., HBM Healthcare Investments, Vivo Capital, venBio,...
BioCentury | Oct 6, 2017
Financial News

Harmony raises $270M, licenses narcolepsy drug

CNS company Harmony Biosciences LLC (Plymouth Meeting, Pa.) said it raised $270 million in an equity round from Valor Equity Partners, Fidelity Management & Research Co., HBM Healthcare Investments, Vivo Capital, venBio, Novo Holdings A/S...
BioCentury | Dec 7, 2016
Clinical News

BCMA-targeting therapies in ASH spotlight

At the American Society of Hematology meeting in San Diego, presentations late Monday highlighted data from Phase I studies of two candidates targeting tumor necrosis factor (TNF) receptor superfamily member 17 (BCMA; TNFRSF17 ; CD269)...
BioCentury | May 26, 2016
Product R&D

H is for cancer

Letting the immune system do the heavy work, a group at Duke University has developed a cancer-killing antibody by studying the blood of atypical lung cancer patients with a slowly progressive form of the disease....
Items per page:
1 - 10 of 184